Introduction
Retinoic acids (RA) modulate the expression of genes necessary for cellular growth and differentiation through the binding of retinoid nuclear receptors that exist as either retinoic acid receptors a, b, g or retinoid X receptors a, b, g.
1 These receptors bind promoter consensus sequences (RAREs) as either RXR-RAR heterodimers or RXR-RXR homodimers. RA restores transcription by inducing conformational changes in the receptors, thereby promoting the release of corepressors and associated histone deacetylase complexes (HDACs) allowing for recruitment of coactivators with histone acetyltransferase (HAT) activity. 2 Acute myeloblastic leukemia (AML) is classified into eight morphological subtypes according to the French American British (FAB) system. The FAB M3 subtype, also called acute promyelocytic leukemia (APL), is distinct from other subtypes based on its sensitivity to retinoids where these agents suppress growth and differentiate the myeloblasts. The addition of the retinoid, all trans retinoic acid (ATRA) to standard chemotherapy improves survival in APL compared to chemotherapy alone. 3 The t(15;17) translocation, which defines retinoid-sensitive cases of APL, results in the generation of a PML-RARa fusion protein with aberrantly high affinity for HDAC complexes. 4 Pharmacological levels of ATRA induce a conformational change in PML-RARa allowing for the release of HDAC complexes and the recruitment of transcriptional coactivators. 5, 6 However, in other forms of AML, retinoids do not induce the same degree of myeloblast differentiation, and have not been shown to improve survival when added to standard chemotherapy. 7, 8 In AML, methylation of CpG islands and chromosomal translocations involving transcription factors are recurrent abnormalities that recruit HDAC activity to promoter regions and might account for the observed insensitivity of non-APL forms of AML towards retinoids. [9] [10] [11] Therefore, direct inhibition of HDAC activity represents a potential mechanism by which retinoid sensitivity can be restored in AML. 12 In this study, we evaluated the effects of the HDAC inhibitor, valproic acid (VPA) on gene expression in AML. An Affymetrix GeneChip experiment demonstrated that VPA modulated the expression of numerous genes in the AML cell line OCI/AML-2; these genes are affected by ATRA in APL cells, 13 but not by ATRA in OCI/AML-2. This included genes important for myeloid differentiation, induction of apoptosis, regulation of cell cycle, and interferon signaling. The combination of ATRA and VPA further accentuated expression of many of these genes, and induced expression of other genes that were not affected by ATRA or VPA alone. In particular p21, a retinoid responsive gene in APL but not AML, was strongly induced by VPA and ATRA þ VPA in AML cells. Induction of p21 expression in the AML samples was associated with the induction of cell cycle arrest. The combination of ATRA and VPA accentuated the cell cycle arrest and promoted apoptosis in the AML samples. These results support ongoing studies that assess the combination of ATRA and HDAC inhibitors in the management of AML.
Materials and methods

Cell culture
NB-4 and OCI/AML-2 cells were cultured in aMEM growth media supplemented with antibiotics and 10% fetal calf serum (HyClone, UT, USA). The clinical AML peripheral blood and bone marrow samples were obtained following informed consent as per institutional research ethics board guidelines. Mononuclear cells were separated by Ficol-Hypaque density centrifugation and resuspended to a final concentration of 10 6 viable cells/ml and cultured in aMEM supplemented with 15% FCS, 10% 5637, 3% kit ligand, and GM-CSF 50 ng/ml. ATRA, 9-cis-retinoic acid (9-cis-RA), and VPA were obtained from Sigma-Aldrich Canada Ltd (ON, Canada). ATRA and 9-cis-RA were given as a single 10 À6 M dose. VPA was dosed at 0.6 mM every 8 h over 24 h.
RNA isolation
Suspension cells were pelleted at 300 g 24 h after drug exposure. Total RNA was isolated using an RNeasy kit (Qiagen Inc., Canada) and stored at À701C in DEPC-H 2 O. Total RNA for the Affymetrix U133A GeneChips was concentrated to 2.5 mg/ml by EtOH precipitation overnight at À201C in 0.3 M sodium acetate pH 5.2 (Sigma-Aldrich Canada Ltd).
Affymetrix GeneChip procedure and data analyses
Biotin-labeled cRNA probes were generated by reverse transcription (RT) from total RNA, and hybridized to the Affymetrix U133A GeneChip according to Affymetrix Inc. protocols (CA, USA). Data was analyzed using Multiple experiment viewer (MeV) version 2.2 (Institute for Genomic Research). Probe sets with probability scores greater than 0.05, indicative of nonspecific hybridization, and displaying less than a two-fold change in signal intensity compared to untreated cells (controls) were not analyzed. Experiments were normalized using standard techniques and clustering was carried out using average linkage method and Pearson correlation. 14 0 CTGCTTCACCACCTTCTTGA. In all, 1 ml of cDNA was used per PCR reaction in a final volume of 50 ml with 2.5 U of Taq DNA polymerase. Annealing temperatures used were 581C for p21 and 551C for GAPDH amplification. All reagents were obtained from Invitrogen Canada Inc. (ON, Canada). PCR products were resolved on ethidium bromide (EB)-stained 1.8% agarose gels. Real-time PCR reactions were performed using 1 ml of cDNA in a final volume of 50 ml with 2 Â SYBR s Green (Applied Biosystems, USA) using an ABI PRISM TM 7700 Sequence Detector.
Protein isolation and Western blotting
In total, 1 Â 10 7 cells were washed in PBS and lysed with RIPA buffer. Immunoblotting was performed according to the standard techniques. 15 Antibodies for hybridization were obtained as follows: p21 polyclonal antibody (Oncogene Research Products, USA), anti-acetyl-histone H3 rabbit polyclonal (anti-AcH3) and anti-acetyl-histone H4 rabbit antiserum (anti-AcH4) antibodies (Upstate Biotechnology, NY, USA), b-actin polyclonal antibody (Sigma-Aldrich Canada Ltd, ON, Canada), and p53 was detected with pAb421 (a kind gift from Dr S Benchimol). Equal protein loading between samples was verified using b-actin hybridization to the PVDF membrane.
Cell cycle analysis
Suspension cells were left in culture for 72 h after drug exposure. In all, 1 Â 10 6 cells were fixed in 95% methanol overnight at 41C, and then washed in PBS containing 0.5% Triton X-100 and 1% bovine albumin (Sigma-Aldrich Canada Ltd, ON, Canada). Cells were resuspended in propidium iodide (PI) 20 mg/ml and RNase 3 mg/ml diluted in PBS and kept at 371C for 1 h protected from light. 16 Analyses were performed on a Beckman Coulter FACscan using ModFit LT software.
Chromatin immunopreciptation (ChIP) assay
A total of 8 Â 10 7 cells were treated under control conditions or with VPA followed by crosslinking in 1% formaldehyde. Nuclei were lysed and the chromatin fragments (300-1000 bp) were generated with repeated 13 W sonications using a Fisher Scientific model 1000 sonicator. Chromatin fragments were immunoprecipitated (IP) overnight at 41C with 3 mg of anti-AcH3 and anti-AcH4 antibodies. 17 Samples were extracted in phenol/ chloroform/isoamyl alcohol (25 : 24 : 1, v/v) and precipitated in EtOH. In total, 50 ml PCR reactions included 7 ml of the IP products and 2.5 U of Platinum Taq DNA polymerase (Invitrogen Life technologies, Canada). Primers amplified a region þ 42 to þ 237 relative to the p21 TATA box: sense 5 0 CCGAA GTCAGTTCCTTGTGG and antisense 5 0 CTGTGAACGCAGCA CACAC. PCR products were resolved on 2.0% EB gels.
Results
VPA restores expression of retinoid response genes in OCI/AML-2 cells
Previously we found that the OCI/AML-2 cell line does not fully differentiate in response to ATRA. 18 Using the U133A Affymetrix GeneChip, OCI/AML-2 cells were examined to determine whether VPA could alter expression of a group of genes that are different from the subset modulated by ATRA, and would recapitulate the class of genes regulated by ATRA in APL cells. Table  1 at the Leukemia website. In some cases, VPA increased or decreased the expression of genes, and the addition of ATRA had no further effect. In other cases, the addition of ATRA either increased or nullified the effect of VPA. The genes that were altered by VPA with or without ATRA were involved with regulation of cell cycle, interferon response, apoptosis, and differentiation. An example of two genes depressed by VPA, but not ATRA, involved in cell cycle regulation are cyclin A2 and MYC, and the decrease in MYC expression was confirmed by Figure 1 , at website). The addition of ATRA to VPA caused a further suppression of these genes. Other genes, such as IRF1, neutrophilic cytosolic factor, ICAM3, and C/EBPb increased in response to ATRA but not VPA; however, the combination of VPA and ATRA further enhanced the expression of these genes. Modulation of IRF1 in this manner was confirmed by RT-PCR (Supplementary material Figure 1 , at website). Examples of genes induced by VPA are cell surface markers CD9, and MHC class II, promoters/enhancers of apoptosis such as MAPK kinase, interferon responsive genes, and caspase 7, and negative regulators of cell cycle like p21 and p19. The addition of ATRA to VPA increased the expression of some, but not all of these genes. Overall, it would appear that VPA had a dramatic effect on the gene expression pattern in OCI/AML-2 cells, and modulated the expression of a set of genes, similar to those modulated by ATRA in APL cells. 13 Alterations in cell cycle, proliferation, and viability of OCI/ AML-2 cells were consistent with the changes in gene expression of p21, MYC, and IRF1. Briefly, ATRA treatment resulted in a modest G1 arrest and minimally reduced cellular proliferation but did not induce apoptosis in the OCI/AML-2 cells. However, VPA treatment induced greater G1 arrest and Figure 1 Hierarchical clustering of the U133A Affymetrix (U133A) GeneChip data comparing OCI/AML-2 treatment groups. Suspension cells, 1 Â 10 6 cells/ml, were exposed to ATRA and/or VPA for 24 h. VPA induces the expression of many genes that code for proteins that are involved in regulation of cell cycle, induction of apoptosis, myeloid differentiation, and interferon signaling that are not modulated by ATRA. The combination of ATRA þ VPA accentuates the expression of many of these genes. C ¼ control, A ¼ ATRA, V ¼ VPA. Table 1 in the Supplementary data (Leukemia website) contains a complete list of genes in descending order as they appear in this hierarchical cluster. reduction in cellular proliferation compared to ATRA and induced apoptosis. The combination of ATRA þ VPA accentuated these responses. The effects of these agents on OCI/AML-2 proliferation and viability are shown in Supplementary material as Figure 2 at the Leukemia website. Expression patterns of p21 and cell cycle responses are discussed in detail in the next section.
RT-PCR (Supplementary material
VPA induces the retinoid response gene p21 and cell cycle arrest in OCI/AML-2 cells
The cell cycle regulator p21 was identified on the Affymetrix GeneChip to be regulated in OCI/AML-2 by VPA, but not ATRA. To confirm this finding, we evaluated the effects of ATRA and VPA on p21 expression and cell cycle in OCI/AML-2 cells; results are summarized in Figure 2a -c. Treatment of OCI/AML-2 cells with ATRA increased expression of p21 mRNA by two-fold but minimally increased p21 protein and induced a modest G1 arrest. The G1 population increased from 69.4% (control cells) to 77.8% (ATRA-treated cells) with a corresponding decrease in the S phase population. There was no increase in the G2M population. In contrast, OCI/AML-2 cells treated with VPA had significantly increased p21 mRNA and protein expression and a high degree of growth arrest in both G1 (Po0.01) and G2M (Po0.001) phases of the cell cycle compared to ATRA-treated cells. The G1 population increased from 69.4% in control cells to 82.3% in VPA-treated cells and the G2M population increased from 5.3 to 9.3% in these treatment groups with a corresponding decrease in S phase. When the combination of ATRA þ VPA was assessed, we found that there was no increase in p21 expression over VPA alone in OCI/AML-2 cells, but that there was a significant increase in the degree of G1 arrest compared to either ATRA (Po0.001) or VPA (Po0.001) alone, with this population increasing to 94.4% of diploid cells.
In addition to assessing the effect of ATRA on OCI/AML-2 cell expression of p21, we also assessed the effect of ATRA and 9-cis-RA on p21 expression in the APL cell line NB-4. As seen in Figure 2d , both ATRA and 9-cis-RA markedly increased the expression of p21 in the NB-4 cells as compared to the OCI/ AML-2 cells. This change in p21 expression in NB-4 cells was associated with cell differentiation (data not shown). Taken together, the above studies indicate that ATRA and 9-cis-RA are inducers of p21 in an APL cell line, but their effect is blocked in the AML cell line OCI/AML-2. However, it is possible to overcome this block by treating cells with the antiseizure medicine VPA; experiments below investigate the nature of this block.
VPA restores p21 expression in OCI/AML-2 cells through HDAC inhibition and not p53
As p53 is a potent inducer of p21, we examined the effects of ATRA and VPA on p53 expression and apoptotic pathways in OCI/AML-2 cells. 19 ATRA treatment increased the expression of p53 protein slightly compared to untreated control cells, whereas VPA, alone or in combination with ATRA, did not increase p53 expression (Figure 3a) . Levels of apoptosis were not affected by any of these treatments (data not shown). These data demonstrate that VPA increases p21 expression and induces cell cycle arrest in OCI/AML-2 cells independently of the p53 pathway.
Having shown that VPA induced p21 independently of p53, we next sought to assess the effect of VPA and ATRA on global acetylation and the acetylation of the p21 promoter, in OCI/ AML-2 cells. Compared to untreated controls, there was only a slight increase in the acetylation of H3 or H4 in ATRA-treated cells, while there was a large increase in the acetylation of H3 and H4 in VPA-treated cells; ATRA þ VPA produced only a marginal increment in acetylation compared to VPA alone (Figure 3b ). Using antibodies against acetylated H3 and H4 histones, we carried out ChIP experiments to assess the changes in histone acetylation on the p21 promoter. The anti-H4 and anti-H3 antibodies showed a specific increase in the amount of p21 promoter immunoprecipitated from VPA-treated cells compared to untreated OCI/AML-2 control cells (Figure 3c ). This supports our hypothesis that VPA induces p21 through histone acetylation and is consistent with previous publications showing that inhibitors of histone deacetylation restore p21 expression. 20 
VPA modulates p21 expression and cell cycle in non-M3 AML clinical samples
To determine whether the effects we observed in OCI/AML-2 cells would translate to primary AML samples, we treated blast cells from patients with ATRA or VPA and measured changes in cell cycle (six cases), apoptosis (six cases), and p21 expression (seven cases). Descriptions of patients that provided AML samples are shown in Table 1 . Several different patterns of response were seen and are summarized in Figure 4a -c. No change was seen in cell cycle or p21 in two samples (AML #2 and #5) with either ATRA or VPA. A third sample (AML #4) showed induction of p21 with VPA treatment but no associated cell cycle arrest. Interestingly, in one of these nonresponders, ATRA actually increased the proportion of cells entering cell cycle with the G1 population decreasing from 94.9% in control cells to 85.4% in the ATRA-treated cells and a corresponding increase in S phase.
Increased expression of p21 was seen in three cases (AML #1, 3, 7) when treated with VPA but not ATRA. Induction of p21 was associated with G1 arrest in two of these samples; cell cycle was not assessed in the third (AML #7). The combination of VPA and ATRA did not further increase p21 expression or G1 arrest in any Figure 4b . Another AML sample (AML #6) demonstrated inducible p21 in response to both ATRA and ATRA þ VPA. Despite ATRA increasing p21 in this sample, there was an increase in the proportion of cells entering cell cycle. Treatment of clinical sample AML #6 with VPA was associated with G2M arrest, where this population increased from 0% in control cells to 5% in VPA-treated cells; the combination of ATRA þ VPA further increased the proportion of cells in G2M to 8.6%. A second difference between the response of the AML cell line OCI/AML-2 and primary cells to VPA was the induction of apoptosis in the primary cells. The level of apoptosis following treatment with ATRA and/or VPA in AML samples #1-6 is shown in Figure 4c . An increase in apotosis due to ATRA was seen only in the sample from AML patient #4 where apoptosis increased from a baseline of 6.5 to 12.9%. In contrast, treatment with VPA increased the apoptotic population in four of the six AML samples (AML #s 3-6); the increase varied from 5.7 to 27.9% over control cells. In particular, VPA treatment induced a greater apoptotic response in cells from AML #4, where the percentage of cells in the sub-G1 peak reached 22.8% compared to 12.9% in the ATRA-treated cells. The addition of ATRA to VPA further increased the apoptotic populations by 5.1-18.9% in AML #s 3-5. It should be emphasized that as a single agent, ATRA did not induce apoptosis in AML #3 and #5, but only did so in these cells when combined with VPA.
Discussion
APL is the first human malignancy in which differentiation therapy using a biologic agent in combination with chemotherapy has resulted in cure. 3, 21 We and others have reported that retinoids, such as ATRA, can inhibit the growth of AML cells in culture and sensitize AML cells to chemotherapy. 18 This has resulted in clinical trials of retinoids and chemotherapy in non-APL patients; in general, the studies have shown no improvement. 7, 8 In an effort to understand the reason for this, we assessed changes in gene expression of AML cells to ATRA and compared those to results obtained by Tamayo et al. 13 In the paper by Tamayo et al, the treatment of the APL cell line NB-4 with ATRA resulted in altered expression of a large proportion of the genes, while we found that the treatment of the AML cell line OCI/AML-2 altered the expression of only a small fraction of the available genes. In the ATRA-treated NB-4 cells, many of the upregulated genes were proapoptotic, or involved in the interferon response pathway, while many of the downregulated genes were antiapoptotic or involved with cell cycle progression. When we compared the list of genes altered in NB-4 13 and OCI/AML-2 (this study), it was apparent that the response to ATRA between the two cell lines was very different. Recently, epigenetic changes such as DNA methylation and histone deacetylation have been found to affect the responsiveness of cells to biologic agents such as ATRA. 22 Ferrara et al 23 have shown that VPA and other histone deacetylase inhibitors can restore ATRA-induced expression of RARb in AML cells. In the studies presented here, we have furthered these studies by identifying genes regulated by VPA and ATRA þ VPA, and characterized the effects on AML cell growth and apoptosis.
By microarray analysis using the Affymetrix U133A array, we found that VPA altered the expression of many more genes than ATRA in the cell line OCI/AML-2. Furthermore, the combination of ATRA þ VPA produced slightly greater changes than VPA alone. Among the classes of genes increased by VPA or the combination of ATRA þ VPA, were genes involved with the induction of apoptosis, while antiapoptotic genes were frequently decreased in expression. The combination of ATRA þ VPA provided interesting results. In some cases, the combination of drug had no further effect beyond VPA alone, while in other cases the combination produced a greater change, for example ATRA caused a slight decrease in expression of MYC, VPA induced a more pronounced effect, and the combination caused even greater suppression of the gene. An intriguing observation, from a therapeutic point of view, was where one of the drugs altered the expression of a gene in a direction opposite to what one would intuitively believe to be beneficial to the goal of cell death or differentiation, while the combination of the drugs drove the expression in the intuitively correct direction. For example, ATRA induced the expression of IRF1, while VPA inhibited its expression. The combination of drugs resulted in an overall increase in IRF1 expression and of greater magnitude compared to ATRA alone. These observations suggest that the combination of drugs is likely to be more beneficial than either agent alone in the treatment of patients.
In keeping with the changes in cell cycle genes, we found that there was a progressive increase in cell cycle arrest as cells were treated with ATRA, VPA, and finally ATRA þ VPA. Among the possible genes that produce cell cycle arrest, we noted on the microarrays that VPA, but not ATRA, resulted in a marked increase in p21 in treated OCI/AML-2 cells. Real time PCR demonstrated that ATRA induced p21 mRNA expression twofold in OCI/AML-2 cells but p21 protein expression did not change significantly. Discrepancy between mRNA and protein expression can occur and the underlying mechanisms were not explored in this study. The minor increase in p21 in OCI/AML-2 cells treated with ATRA is likely due to p53, 24 but the induction by VPA appears to be a p53-independent mechanism. The mechanism of p21 induction by VPA and ATRA þ VPA appears to be through changes in histone acetylation, as increased acetylation was seen specifically at the p21 promoter, and globally. The combination of ATRA þ VPA produced a greater G1 arrest than VPA alone, yet there was no increase in p21 induction, therefore implicating the induction of other genes involved in growth arrest.
The above studies were carried out using an established cell line. To show the applicability to primary AML samples, the cells from seven cases were treated with ATRA, VPA, and ATRA þ VPA; variability in response was seen. ATRA did not induce cell cycle arrest to any significant degree in any sample. In one sample, VPA caused a G1 arrest without evidence of increased p21; the possibility that cyclin degradation was involved was not explored. 25 VPA increased expression of p21 in five of seven patients. In addition to the increased expression of p21, there was evidence of cell cycle arrest with VPA and ATRA þ VPA in the patient samples. In contrast to the cell line OCI/AML-2, VPA and particularly ATRA þ VPA induced apoptosis in the majority of patient samples. This extends previous reports of VPA-induced apoptosis in human leukemic cells lines. 26 In conclusion, we demonstrate in this paper that VPA, through inhibition of histone deacetylases, induces changes in gene expression and enhances the responsiveness of AML cells to ATRA. During the review of this paper, Kuedgen et al 27 published on the clinical improvement in 44% of patients treated with ATRA þ VPA. Those results, and the patient-topatient variation seen here, indicate that this combination is of potential therapeutic value in the treatment of AML, most likely in combination with other chemotherapeutics. The variability between patients observed in our study and that of Kuedgen will have to be taken into account in any clinical trial. Certainly, means to predict responsiveness are required; p21 induction could be such a marker.
